Innovive and Attentive Science Forge Alliance in Middle East Biotech Boom

SAN DIEGO, CA – April 28, 2026 – San Diego-based Innovive, LLC, a pioneer in single-use vivarium technology, has announced a strategic partnership with Attentive Science Ltd., positioning itself at the epicenter of the Middle East's burgeoning life sciences revolution. The distribution and co-marketing agreement will introduce Innovive’s portfolio of wash-free, recyclable animal caging systems to the rapidly expanding research and development landscape across the Gulf Cooperation Council (GCC) and broader Middle East and North Africa (MENA) regions.

This collaboration aims to equip a new generation of laboratories in the UAE, Saudi Arabia, Qatar, and beyond with infrastructure designed to accelerate preclinical research while significantly reducing costs, labor, and environmental impact. By leveraging Attentive Science’s regional expertise and state-of-the-art facilities in Abu Dhabi’s Masdar City, Innovive is making a strategic entry into one of the world's most dynamic and well-funded biotech markets.

“This partnership represents a major milestone in our international growth strategy,” said Jamie Blose, Pharm. D, MBA, JD, Chief Executive Officer at Innovive. “Attentive Science brings deep regional expertise, regulatory knowledge, and a state-of-the-art vivarium facility that will serve as a premier demonstration site for our technology in the Middle East.”

A Region Primed for Scientific Advancement

The Innovive-Attentive Science alliance is not happening in a vacuum. It is a calculated move capitalizing on unprecedented investment and ambition within the GCC and MENA regions. The Middle East and Africa pharmaceutical market, valued at over $75 billion in 2024, is projected to soar to more than $141 billion by 2034. The regional biotechnology market shows even more explosive potential, with analysts forecasting a compound annual growth rate (CAGR) of 13.5% through 2030.

This growth is fueled by ambitious national strategies. Saudi Arabia’s Vision 2030 and the UAE’s Abu Dhabi Vision 2030 have identified biotechnology and pharmaceuticals as key pillars for economic diversification away from hydrocarbons. Saudi Arabia, which launched its National Biotechnology Strategy in 2024, aims to become a dominant biotech leader in MENA by 2030. The UAE is concurrently cultivating a vibrant ecosystem in Masdar City, which has already attracted over $272 million in foreign direct investment and is home to more than 50 life science companies. These government-led initiatives are pouring billions into creating advanced laboratory facilities, R&D centers, and a regulatory environment conducive to innovation.

As the prevalence of chronic diseases rises and healthcare expenditure in the GCC is projected to exceed $100 billion annually, the demand for locally developed and tested therapeutics is surging. This partnership directly addresses the foundational need for advanced preclinical infrastructure to support this domestic R&D boom.

Redefining the Modern Vivarium

At the heart of this collaboration is Innovive's disruptive technology: a single-use, individually ventilated caging (IVC) system for small animal models, which are critical for preclinical drug development. For decades, research vivariums have relied on traditional, reusable cages that require massive, resource-intensive industrial washrooms. These facilities demand huge capital investments, significant physical space, and constant labor for washing, sterilizing, and handling cages.

Innovive’s system eliminates this entire workflow. The company’s patented cages are made from recyclable PET plastic, arrive irradiated and ready for use, and are disposed of after a single use. This “wash-free” model offers a paradigm shift in operational efficiency. Case studies suggest that building a vivarium with this disposable system can cost up to two-thirds less than a traditional facility. The operational savings are equally compelling, with reported reductions of over 97% in water use and more than 50% in energy consumption for HVAC systems.

Furthermore, the technology enhances scientific integrity and animal welfare. The sealed, HEPA-filtered cages provide superior biosecurity, minimizing contamination risks. Studies have shown that ammonia levels inside these disposable cages are up to 15 times lower than in conventional caging, creating a healthier environment for the animals. For research staff, the lightweight, ergonomic design reduces physical strain and repetitive injuries associated with handling heavy traditional cages.

Innovive has also addressed the environmental concerns of a single-use model with a closed-loop recycling program. Through its sister company, Innocycle, used plastic is collected and fully recycled, while used bedding is composted, aligning with a zero-landfill mission and reducing the carbon footprint by up to 70% compared to a wash-based system.

A Synergy of Global Innovation and Regional Expertise

The partnership structure is designed for maximum impact. Attentive Science, recognized as the region’s first licensed preclinical contract research organization (CRO), provides the critical on-the-ground infrastructure and market access. Headquartered in Masdar City, the company delivers high-quality, GLP-compliant studies in toxicology, bioanalysis, and translational research, with a focus on advanced therapeutics like cell and gene therapies.

Under the agreement, Attentive Science will not only distribute Innovive’s complete portfolio of caging systems and consumables but will also feature the technology in its own state-of-the-art vivarium. This facility will act as a living showroom, allowing regional research institutions to witness the system’s benefits firsthand. This synergy is expected to drive rapid adoption across a region that is actively building new research capacity from the ground up.

Tareq Abu-Nadi, CEO & Co-Founder of Attentive Science, highlighted this alignment, stating, “Innovive’s single-use housing technology aligns perfectly with the rapid growth of biomedical research infrastructure in the GCC and MENA region. We are proud to serve as Innovive’s regional partner and to introduce advanced, biosecure, and workflow-optimized solutions to research institutions across the region.”

This collaboration also taps into a favorable regulatory tide. Both the UAE and Saudi Arabia have recently implemented reforms to streamline and accelerate the approval process for innovative drugs. By providing efficient and reliable preclinical infrastructure, the partnership helps local and international companies generate the high-quality data needed to navigate these new, faster pathways to market. This move ultimately strengthens the global drug development pipeline by creating a robust, efficient, and strategically located hub for early-stage research, reinforcing Abu Dhabi’s role as a rapidly emerging force in life sciences innovation.